Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and Vitamin K antagonists: A systematic review and meta-Analysis

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Skaistis, Joel ^a   Tagami, Travis ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CONTROLLED STUDY; EXTRACRANIAL BLEEDING; HUMAN; META ANALYSIS; MORTALITY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM PROPHYLAXIS; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; HEMORRHAGE; ODDS RATIO; ORAL DRUG ADMINISTRATION; RISK;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HEMORRHAGE; HUMANS; ODDS RATIO; RISK; VITAMIN K;

EID: 84946569791     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137444     Document Type: Review

References (44)

1. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 09/15; 365(11):981-992. doi: 10.1056/NEJMoa1107039
2. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 11/28; 369(22):2093-2104. doi: 10.1056/NEJMoa1310907
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 09/17; 361(12):1139-1151. doi: 10.1056/NEJMoa0905561
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 09/08; 365(10):883-891. doi: 10.1056/NEJMoa1009638
5. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 12/23; 363 (26):2499-2510. doi: 10.1056/NEJMoa1007903
6. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012 02/01; 141(2):e44S-88S. doi: 10.1378/chest.11-2292
7. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011 October 04; 124(14):1573-1579. doi: 10.1161/CIRCULATIONAHA.111.029017
8. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108(8):217-224.
9. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (beriplex P/N) in a rabbit model. Journal of Thrombosis and Haemostasis. 2012; 10(9):1841-1848. doi: 10.1111/j.1538-7836.2012.04859.x
10. Van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. 13th Congress of the European Hematology Association [abstract] Haematologica 2008; 93:148 0370.
11. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, et al. Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood. PLoS ONE 2013; 11(8):e78696.
12. Anne-Celine M, Bernard L, Thomas L et al. Evaluation of recombinant activated factor vii, prothrombin complex concentrate and fibrinogen concentrate to reverse apixaban in a rabbit model. J Am Coll Cardiol 2012 03/27; 59(13):E573.
13. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor xa. Nat Med 2013; 19(4):446-451. doi: 10.1038/nm.3102
14. Cohen, Michael R. Monitoring FDA MedWatch Reports: Signals for Dabigatran and Metoclopramide. Data from 2011 Quarter 1. Available: http://www.ismp.org/QuarterWatch/pdfs/2011Q1.pdf. Accessed 28 August 2014.
15. Cohen, Michael R. Anticoagulants the Leading Reproted Drug Risk in 2011. New Data from 2011 Quartes 3-4. Available: http://www.ismp.org/QuarterWatch/pdfs/2011Q4.pdf. Accessed 28 August 2014.
16. Skaistis, Joel. Risk of bleeding-related fatalities with reversible and non-reversible oral anticoagulants: A systematic review and meta-Analysis. Available: http://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42014013294#.VXUQI89Viko. Accessed 8 June 2015.
17. The Cochrane Collaboration's tool for assessing risk of bias. Available: http://ohg.cochrane.org/sites/ohg.cochrane.org/files/uploads/Risk%20of%20bias%20assessment%20tool.pdf. Accessed 28 August 2014.
18. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 08/29; 369(9):799-808. doi: 10.1056/NEJMoa1302507
19. Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: Insights from the ARISTOTLE trial. Eur Heart J. 2014 12/12.
20. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 04/05; 366(14):1287-1297. doi: 10.1056/NEJMoa1113572
21. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 10/10; 369(15):1406-1415. doi: 10.1056/NEJMoa1306638
22. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in japanese patients with atrial fibrillation-The J-ROCKET AF study. Circulation Journal. 2012; 76 (9):2104-2111.
23. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 12/10; 361(24):2342-2352. doi: 10.1056/NEJMoa0906598
24. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 February; 129(7):764-772. doi: 10.1161/CIRCULATIONAHA.113.004450
25. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-Term anticoagulant therapy (RE-LY) trial. Circulation 2011 May 31; 123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747
26. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 02/21; 368(8):709-718. doi: 10.1056/NEJMoa1113697
27. Prins M, Lensing A, Bauersachs R, van Bellen B, Bounameaux H, Brighton T, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal. 2013; 11(1):21. doi: 10.1186/1477-9560-11-21
28. A Dose Response Study of Dabigatran Etexilate (BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillaion in Comparison to Warfarin. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[6/7/15]. Available: https://clinicaltrials.gov/ct2/show/study/NCT01136408?term=NCT01136408&rank=1 Identifier: NCT01136408.
29. Buller HR, Lensing AWA, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The Einstein DVT Dose-Ranging Study. Blood. 2008 07/11; 112(6):2242-7. doi: 10.1182/blood-2008-05-160143
30. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, et al. Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study. Circulation. 2007 07/10; 116(2):180-7.
31. Ogawa S, Shinohara Y, Kanmuri K. Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial Fibrillation;-The ARISTOTLE-J Study-. Circulation Journal. 2011; 75(8):1852-9.
32. Buller H, Deitchman D, Prins M, Segers A et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis. 2008 08/01; 6(8):1313-8. doi: 10.1111/j.1538-7836.2008.03054.x
33. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010; 104(9):633-41.
34. Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamaguchi T, et al. Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation. Circulation Journal. 2012; 76(8):1840-7.
35. Chung N, Jeon H, Lien L, Lai W, Tse H, Chung W, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost. 2011; 105(3):535-45. doi: 10.1160/TH10-07-0451
36. Palareti G. Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding. Semin Hematol 2014 04/01; 51(2):102-111. doi: 10.1053/j.seminhematol.2014.02.002
37. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-Analysis of randomised trials. The Lancet 2015/06; 383(9921):955-62.
38. Hankey GJ, Stevens SR, Piccini JP, Lokhnygina Y, Mahaffey KW, Halperin JL, et al. Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation. Stroke. 2014 05/01; 45(5):1304-12. doi: 10.1161/STROKEAHA.113.004506
39. Majeed A, Hwang H, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013 11/19; 128 (21):2325-2332. doi: 10.1161/CIRCULATIONAHA.113.002332
40. Hart RG, Diener H, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial. Stroke. 2012 06/01; 43(6):1511-7. doi: 10.1161/STROKEAHA.112.650614
41. Sardar P, Chatterjee S, Herzog E, Nairooz R, Mukherjee D, Halperin JL. Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-Analysis of Randomized Trials. Can J Cardiol 2015/06; 30 (8):888-97.
42. Dentali F, Riva N, Crowther M, Turpie AGG, Lip GYH, Ageno W. Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature. Circulation. 2012 11/13; 126(20):2381-91. doi: 10.1161/CIRCULATIONAHA.112.115410
43. Francia P, Adduci C, Santini D, Musumeci B, Tocci G. New Oral Anticoagulants in Non-Valvular Atrial Fibrillation. High Blood Pressure & Cardiovascular Prevention. 2013 06/01; 20(2):53-60.
44. Palareti G. Direct Oral Anticoagulants and Bleeding Risk (in Comparison to Vitamin K Antagonists and Heparins), and the Treatment of Bleeding. Semin Hematol 2015/06; 51(2):102-11.